Numerous efforts to understand the functional roles of antibodies demonstrated that they can
protect against malaria. However, it is unclear which antibody responses are the best …

To treat current infectious diseases, different therapies are used that include drugs or
vaccines or both. Currently, the world is facing an increasing problem of drug resistance …

Background Major gaps in our understanding of Plasmodium vivax biology and the
acquisition of immunity to this parasite hinder vaccine development. P. vivax merozoites …

The Plasmodium falciparum reticulocyte-binding protein homolog 5 (PfRH5) has recently
emerged as a leading candidate antigen against the blood-stage human malaria parasite …

Malaria transmission begins when an infected mosquito delivers Plasmodium sporozoites
into the skin. The sporozoite subsequently enters the circulation and infects the liver by …

Abstract Background Transmission-blocking vaccines (TBVs) have become a focus of
strategies to control and eventually eliminate malaria as they target the entry of sexual stage …

Genetic variability in Plasmodium falciparum malaria parasites hampers current malaria
vaccine development efforts. Here, we hypothesize that to address the impact of genetic …

The malaria vaccine BK-SE36 is a recombinant protein (SE36) based on the Honduras 1
serine repeat antigen-5 of Plasmodium falciparum, adsorbed to aluminium hydroxide gel …

To satisfy the rapidly increasing biopharmaceutical market, a broad variety of microbial
protein expression systems is requested by the industry. High demands are made on safety …

Despite decades of research and the availability of effective medications, malaria remains a
significant global health issue. The vast majority of infections are caused by two species …